SLDB logo

Solid Biosciences Inc. (SLDB)

$6.23

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SLDB

Market cap

$695333608

EPS

-1.76

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

2.645914

Price on SLDB

Previous close

$6.48

Today's open

$6.48

Day's range

$6.10 - $6.57

52 week range

$4.16 - $11.45

Profile about SLDB

CEO

Bo Cumbo

Employees

121

Headquarters

Charlestown, MA

Exchange

Nasdaq Global Select

Shares outstanding

111610531

Issue type

Common Stock

SLDB industries and sectors

Healthcare

Biotechnology & Life Sciences

News on SLDB

Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing

Solid Biosciences NASDAQ: SLDB plans to meet with the U.S. Food and Drug Administration before the end of 2026 to discuss a potential accelerated approval pathway for its Duchenne muscular dystrophy gene therapy, CEO Bo Cumbo said at a Jefferies fireside chat.

news source

MarketBeat • Nov 17, 2026

news preview

Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

CHARLESTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conference: 2026 Jefferies Global Healthcare Conference in London Bo Cumbo, President and CEO, will participate in a fireside chat on Monday, November 16, 2026, at 2:30 p.m.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

CHARLESTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that members of management will participate in one-on-one investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference taking place in Boston, MA on Monday, November 9, 2026.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates

- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 -

news source

GlobeNewsWire • Nov 4, 2026

news preview

Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia

- Obtaining Orphan designation from the European Commission reflects Solid's commitment to the global development of SGT-212 for individuals living with Friedreich's ataxia - - SGT-212 is a first-in-class dual route FA gene therapy designed to combine direct, MRI-guided delivery to the dentate nuclei with systemic delivery to reach cardiac and other systemic tissues - - Five participants have been dosed in the ongoing Phase 1b FALCON clinical trial and SGT-212 has been well tolerated as of October 5, 2026 - - Solid expects to report initial FALCON clinical data in Q1 2027 - CHARLESTOWN, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the European Commission (EC), acting upon the positive opinion of the European Medicines Agency's Committee for Orphan Medicinal Products, has granted Orphan designation to SGT-212 for the treatment of Friedreich's ataxia (FA).

news source

GlobeNewsWire • Oct 26, 2026

news preview

Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026

CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that seven abstracts have been accepted for poster presentation at the 33rd European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany.

news source

GlobeNewsWire • Oct 20, 2026

news preview

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units (“RSUs”) to one newly hired employee.

news source

GlobeNewsWire • Oct 1, 2026

news preview

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations

Solid Biosciences is a speculative buy, leveraging a differentiated SGT-003 gene therapy for Duchenne muscular dystrophy with a credible cash runway into mid-2028. SLDB's investment thesis centers on building both biological and controlled functional evidence, not just microdystrophin expression, to address physician and regulatory concerns. Competitive positioning against Sarepta and Regenxbio hinges on achieving clinically meaningful differentiation in function, safety, and eligibility, with time pressure from advancing rivals.

news source

Seeking Alpha • Sep 25, 2026

news preview

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

news source

Seeking Alpha • Sep 10, 2026

news preview

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare Conference Bo Cumbo, President and CEO, and Gabriel Books, M.D.

news source

GlobeNewsWire • Sep 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Solid Biosciences Inc.

Open an M1 investment account to buy and sell Solid Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SLDB on M1